A carregar...
The Type II anti-CD20 Antibody Obinutuzumab (GA101) is More Effective than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
OBJECTIVE: Depleting pathogenic B cells could treat SLE. However, depleting B cells in the presence of an inflammatory setting such as lupus is difficult. We hypothesized that a Type II anti-CD20 mAb with a different mechanism–obinutuzumab (GA101)—could be more effective in depletion in lupus and th...
Na minha lista:
| Publicado no: | Arthritis Rheumatol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8084886/ https://ncbi.nlm.nih.gov/pubmed/33277983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41608 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|